NCT00003665View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

October 31, 2002

Study Completion Date

November 30, 2002

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

dendritic cell-MART-1 peptide vaccine

BIOLOGICAL

gp100 antigen

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

BIOLOGICAL

tyrosinase peptide

Trial Locations (1)

19104-4283

University of Pennsylvania Cancer Center, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH